Boundless Bio Cuts Staff as Lead Drug Faces SetbacksBoundless BioBoundless Bio restructures after setbacks in its lead oncology trials, laying off 33% of staff and shifting focus to a new drug combination strategy and advancing its kinesin degrader candidate BBI-940.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
